Zealand Pharma A/S (ZEAL) 2014年年度报告「NASDAQ」.pdf

1、AS PIONEERING LEADERS IN THE DESIGN AND DEVELOPMENT OF PEPTIDE MEDICINESWE ARE EXCITED ABOUT OUR FUTURE WITH 2015 AS A CATALYST YEARIN 2014,WE SET THE SCENE FOR ACCELERATED VALUE GROWTHZEALAND PHARMA A/S ANNUAL REPORT 2014REVOLUTIONARY HEALTH SOLUTIONSFront cover features all employees and Executive

2、 Management of Zealand PharmaCONTENTSMANAGEMENT REVIEWZealand at a glance 2Letter from the Chairman 4Letter from the CEO 5Key figures 6Financial highlights 7Key Performance Indicators 8Strategy 9Business model 10Financial guidance for 2015 11Portfolio overview 122014 achievements and 2015 catalysts

3、14Product and development portfolio 16Risk management and internal control 28Corporate governance 30Corporate Social Responsibility 31Board of Directors 32Executive Management 34Shareholder information 36Financial review 40Statement of the Board of Directors and Executive Management 42Independent au

4、ditors report 43FINANCIAL STATEMENTSFinancial statements 44Notes 49Product and development portfolio16-28Zealand at a glance2-3Shareholder letters4-5Management Review1Zealand Pharma A/S Annual Report 2014Zealand at a glance|Shareholder letters|Financial highlights|KPI&strategy|Business model|Portfol

5、io overview|2014 achievements and 2015 catalysts|Product and development portfolio|Executive Management|Shareholder information|Financial review|Financial statementsZEALAND AT A GLANCEBroad portfolio of novel medicines:One marketed several in development We are advancing a broad portfolio of novel m

6、edicines,partly wholly-owned,partly under partnership.Lyxumia for Type 2 diabetes is marketed globally(ex-US)by Sanofi.US regulatory submission expected in Q3 2015.Five products in clinical development:LixilLan-Phase III for Type 2 diabetes(Sanofi);danegaptide-Phase II for cardiac injuries;elsigluti